A Study of GKL-006 Injection in Patients With Advanced Pancreatic Cancer

This is a Phase I/IIa, multicenter study designed to evaluate the safety, tolerability, and efficacy of GKL-006 injection in patients with ductal adenocarcinoma of pancreas.

Trial Details

NCT ID
NCT07777211
Phase
PHASE1 / PHASE2
Sponsor
Beijing Gene Key Life Technology Co., Ltd
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • GKL-006 injection
  • Nab-paclitaxel and Gemcitabine
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • Aged 18-75 years, inclusive, with no sex restriction.
  • Histologically or cytologically confirmed unresectable locally advanced or metastatic PDAC.
  • No prior systemic therapy for unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma. Prior neoadjuvant or adjuvant therapy w…
  • For patients with postoperative recurrence or metastasis who previously received neoadjuvant or adjuvant therapy, disease progression or recurrence…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →